At Matrix45, we view the the follow-on biologics space along 8 dimensions. Each dimension may pose some challenges but also create opportunities to provide accessible, quality, cost-responsible, and equitable biological therapy.
Risk Management
Interchangeability | Efficacy Failure | Safety Failure |
Supply Chain Disruptions
Legal
Exclusivity | Patents | Patent Thickets | Clinical Practice
Regulatory
Jurisdiction to Global | Interchangeability
Clinical
Therapeutic Choice | Interchangeability | Post-approval Evidence
Markets
Choice | Competition | Access and Entry | Sustainability |
| Volume and Commoditization | Globalization | LMICs
Value and Economics
Competition | Cost-Efficiency | Expanded Access | Affordability |
Price Erosion | Alternate Metrics
Advocacy
Patient Choice | Clinician Options | Guidelines | Patient Equity
Society
Cost-Responsible Care | Choice | Expanded Access |
Patient Equity
Biosimilars and Beyond 